Belite Bio CEO sells 9,200 ADS under 10b5-1 plan

Belite Bio Chief Executive Officer Lin Yu-Hsin reported open-market sales of 9,200 American depositary shares (ADS) of Belite Bio, Inc. on April 9, 2026.

Rhea-AI Filing Summary

Belite Bio Chief Executive Officer Lin Yu-Hsin reported open-market sales of 9,200 American depositary shares (ADS) of Belite Bio, Inc. on April 9, 2026. The ADS were sold in multiple transactions at weighted average prices ranging from $180.00 to $183.00 per ADS.

The filing states that these sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025. After the transactions, Lin held 170,934 ADS directly. Each ADS represents one ordinary share of Belite Bio.

Insider Trade Summary 10b5-1

Net Seller: 9,200 shares

Net Sell 4 txns

Insider Lin Yu-Hsin

Role Chief Executive Officer

Sold 9,200 shs ($1.67M)

Type	Security	Shares	Price	Value
Sale	American depositary share	2,500	$180.3578	$451K
Sale	American depositary share	3,500	$181.3304	$635K
Sale	American depositary share	3,000	$182.396	$547K
Sale	American depositary share	200	$183.00	$37K

Holdings After Transaction: American depositary share — 170,934 shares (Direct)

Footnotes (5)

1. F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025.
3. F3. Represents the weighted average price of shares sold at prices that ranged from $180.00 to $180.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. F4. Represents the weighted average price of shares sold at prices that ranged from $181.00 to $181.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. F5. Represents the weighted average price of shares sold at prices that ranged from $182.00 to $182.89. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Key Figures

ADS sold: 9,200 ADS Remaining holdings: 170,934 ADS Sale price range (block 1): $180.00–$180.99 +3 more

6 metrics

ADS sold 9,200 ADS Total American depositary shares sold on April 9, 2026

Remaining holdings 170,934 ADS CEO’s direct ownership after reported sales

Sale price range (block 1) $180.00–$180.99 Prices underlying weighted average of $180.3578

Sale price range (block 2) $181.00–$181.96 Prices underlying weighted average of $181.3304

Sale price range (block 3) $182.00–$182.89 Prices underlying weighted average of $182.3960

Highest reported price $183.00 per ADS Price for final 200-share transaction

Key Terms

American depositary share, Rule 10b5-1 trading plan, weighted average price

3 terms

American depositary share financial

"Each American depositary share represents one ordinary share, par value US$0.0001 per share"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"Represents the weighted average price of shares sold at prices that ranged from $180.00 to $180.99"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Belite Bio (BLTE) report for CEO Lin Yu-Hsin?

Belite Bio reported that CEO Lin Yu-Hsin sold 9,200 American depositary shares in open-market transactions. These sales occurred on April 9, 2026 at prices around $180–$183 per ADS and were executed under a pre-arranged Rule 10b5-1 trading plan.

How many Belite Bio (BLTE) shares does the CEO hold after the reported sale?

After the reported transactions, CEO Lin Yu-Hsin directly holds 170,934 American depositary shares of Belite Bio. This figure reflects his remaining position following the April 9, 2026 open-market sales disclosed in the Form 4 insider trading report.

At what prices did Belite Bio (BLTE) CEO Lin Yu-Hsin sell his shares?

The CEO’s sales occurred at weighted average prices between about $180.00 and $183.00 per American depositary share. Footnotes explain that individual trades ranged from $180.00 to $182.89, with precise breakdowns available upon request to the company or SEC staff.

Was the Belite Bio (BLTE) CEO’s stock sale made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by CEO Lin Yu-Hsin on December 23, 2025. Such pre-arranged plans automate trades over time and can reduce the significance of transaction timing as a signal.

What does each Belite Bio (BLTE) American depositary share represent?

Each Belite Bio American depositary share represents one ordinary share of the company, with a par value of US$0.0001 per share. Investors trading BLTE ADS on U.S. markets are effectively buying or selling the underlying ordinary shares on a one-for-one basis.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lin Yu-Hsin

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	04/09/2026		S(2)		2,500	D	$180.3578(3)	177,634	D
American depositary share(1)	04/09/2026		S(2)		3,500	D	$181.3304(4)	174,134	D
American depositary share(1)	04/09/2026		S(2)		3,000	D	$182.396(5)	171,134	D
American depositary share(1)	04/09/2026		S(2)		200	D	$183	170,934	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/23/2025.

3. Represents the weighted average price of shares sold at prices that ranged from $180.00 to $180.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

4. Represents the weighted average price of shares sold at prices that ranged from $181.00 to $181.96. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

5. Represents the weighted average price of shares sold at prices that ranged from $182.00 to $182.89. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

	/s/ Yu-Hsin Lin	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)